Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02054130 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma
A Phase 2 study of Asthma, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 584
- Enrollment target
- 20
- Study locations
NCT02054130: Completed Phase 2 study of Asthma, sponsored by MedImmune.
NCT02054130 is a Phase 2 study of Asthma that has completed, run by MedImmune. The registered enrollment target is 584 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02054130, a Phase 2 study of Asthma, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 584 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
Primary Outcome
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MEDI9929 70 mg
- DRUG MEDI9929 210 mg
- DRUG MEDI9929 280 mg
Study Locations (20)
California
- Research Site - Los Angeles
- Research Site - Los Angeles
Florida
- Research Site - Miami
- Research Site - Oviedo
New York
- Research Site - New York
- Research Site - New York
North Carolina
- Research Site - Charlotte
- Research Site - Charlotte
South Carolina
- Research Site - Rock Hill
- Research Site - Spartanburg
Other
- Research Site - Plovdiv
- Research Site - Sofia
Georgia
- Research Site - Savannah
Illinois
- Research Site - Peoria
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 584 participants |
| Start Date | 2013-12-13 |
| Est. Completion | 2017-03-01 |
| Phase | Phase 2 |
What the finished NCT02054130 record still lists
NCT02054130 is an interventional study that assigns participants to a tested intervention. The registered 584 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02054130 names 20 study sites across 14 states, led by California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT02054130 about?
NCT02054130 is a clinical study titled "Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma". The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.
What is the current status of trial NCT02054130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 584 participants. The study started on 2013-12-13. Estimated completion is 2017-03-01.
What conditions does trial NCT02054130 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02054130?
The interventions under investigation include: Placebo (DRUG), MEDI9929 70 mg (DRUG), MEDI9929 210 mg (DRUG), MEDI9929 280 mg (DRUG).
Who is sponsoring clinical trial NCT02054130?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02054130 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02054130's enrollment target sits among peer trials
584 70th of 374 higher than 305 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03840083 · 584 participants · NA
Sleep-dependent Learning in Aging
- NCT04984291 · 584 participants · NA
Zimmer Biomet Shoulder Arthroplasty PMCF
- NCT05983757 · 584 participants · NA
Combined Thrombectomy for Distal MediUm Vessel Occlusion StroKe
- NCT06569290 · 584 participants · NA
Refinement and Testing of Recruitment Methodology for Behavioral Medication Adherence Interventions Using Behavioral Science-based Approaches
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI